

ESP Advanced Training Centre in the area of Molecular Pathology
Heidelberg, Germany

Specialist fields and techniques (open also to technicians/medical scientists)

Molecular pathology

Centre specification

Name of the centre and address

Institute of Pathology

University Hospital Heidelberg

Im Neuenheimer Feld 224

69120 Heidelberg

Chair of the centre

Prof. Dr. P. Schirmacher

Head of the training programme

Prof. Dr. P. Schirmacher

Details about specific training areas (particular method, field of subspeciality)

Molecular Pathology

Conditions

The center will offer one trainee position in Molecular Pathology at a time. The duration should be not more than 3 months, shorter periods are possible for applicants with advanced knowledge. We accept applicants all year round except for middle December till middle of January and during August/beginning of September. We will not charge the training and support will be given in finding an accommodation for a reasonable local price. If required we will support the applicant to obtain the necessary visa and other documents and send a letter of invitation as well as we will agree on duration and time of the stay beforehand. After completion of the training period the trainee will receive a detailed certificate describing the work.

Contact address for requests

Dr. Mandy Skunde

Institute of Pathology

Im Neuenheimer Feld 224, room 1.007

69120 Heidelberg

Tel: +49/ 6221 56 39186

Email: mandy.skunde@med.uni-heidelberg.de

Attachments:

1. Training measures
2. Publications of the last 5 years
3. Seminars and Diagnostic courses at the Institute of Pathology
4. Previous guests
5. Flyer displaying the molecular technologies

Attachment 1:**Molecular Pathology training measures:**

Participation in processing/evaluation of daily routine cases (~4000 cases p.a.)

Hands- on training in molecular pathology center

Participation in molecular pathology research project

Participation in internal training measures (3 h weekly)

Residents training meeting (1h weekly)

Research in progress meeting (1h weekly)

Journal Club (1 h weekly)

Participation in regular interdisciplinary meetings (1 h weekly)

Molecular tumor board with NCT (1 h weekly)

Lung Tumor board (with strong emphasis on Molecular diagnostics) (1 h weekly)

Trainers (Board certified Pathologists with high expertise in Molecular Pathology and experienced Molecular Biologists with routine molecular pathology expertise):

Dr. A. Stenzinger

Dr. S. Singer

Dr. F. Lasitschka

Dr. R. Penzel

Dr. V. Endris

Dr. R. Brand

Dr. A.-L. Volckmar

Attachment 2: Publications of the last 5 years

Publications 2015

De Ponti A, Wiechert L, Schneller D, Pusterla T, Longeric T, Hogg N, Vogel A, Schirmacher P, Hess J, Angel P. A pro-tumorigenic function of

S100A8/A9 in carcinogen-induced hepatocellular carcinoma. *Cancer Lett.* 2015 Dec 28;369(2):396-404.

De Ponti A, Wiechert L, Stojanovic A, Longeric T, Marhenke S, Hogg N, Vogel A, Cerwenka A, Schirmacher P, Hess J, Angel P. Chronic liver

inflammation and hepatocellular carcinogenesis are independent of S100A9. *Int J Cancer.* 2015 May 15;136(10):2458-63

Elgohary N, Pellegrino R, Neumann O, Elzawahry HM, Saber MM, Zeeneldin AA, Geffers R, Ehemann V, Schemmer P, Schirmacher P,

Longeric T. Protumorigenic role of Timeless in hepatocellular carcinoma. *Int J Oncol.* 2015 Feb;46(2):597-606.

Flechtenmacher C, Schirmacher P, Schemmer P. Donor liver histology--a valuable tool in graft selection. *Langenbecks Arch Surg.* 2015

Jul;400(5):551-7. doi: 10.1007/s00423-015-1298-7. Epub 2015 Mar 26. PubMed PMID: 25809015.

Goepfert B, Frauenschuh L, Zucknick M, Roessler S, Mehrabi A, Hafezi M, Stenzinger A, Warth A, Pathil A, Renner M, Schirmacher P,

Weichert W. Major histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary

tract cancer. *Br J Cancer.* 2015 Nov 3;113(9):1343-9.

Graham RP, Jin L, Knutson DL, Kloft-Nelson SM, Greipp PT, Waldburger N, Roessler S, Longeric T, Roberts LR, Oliveira AM, Halling KC,

Schirmacher P, Torbenson MS. DNAJB1-PRKACA is specific for fibrolamellar carcinoma. *Mod Pathol.* 2015 Jun;28(6):822-9. doi:

10.1038/modpathol.2015.4. Epub 2015 Feb 20.

Hiet MS, Bauhofer O, Zayas M, Roth H, Tanaka Y, Schirmacher P, Willemsen J, Grünvogel O, Bender S, Binder M, Lohmann V, Lotteau V,

Ruggieri A, Bartenschlager R. Control of temporal activation of hepatitis C virus-induced interferon response by domain 2 of nonstructural

protein 5A. *J Hepatol.* 2015Oct;63(4):829-37. 22: Bartels S, Lehmann U, Büsche G, Schlue J, Hussein K, Debatin D, Karcher A, Andrusis M,

Schirmacher P, Kreipe H. De novo CSF3R mutation associated with transformation of myeloproliferative neoplasm to atypical CML. *Ann*

Hematol. 2015 Jul;94(7):1255-6.

Hoffmann K, Unsinn M, Hinz U, Weiss KH, Waldburger N, Longerich T, Radeleff B, Schirmacher P, Büchler MW, Schemmer P. Outcome after

a liver resection of benign lesions. *HPB (Oxford).* 2015 Nov;17(11):994-1000.

Knoll M, Macher-Goeppinger S, Kopitz J, Duensing S, Pahernik S, Hohenfellner M, Schirmacher P, Roth W. The ribosomal protein S6 in renal

cell carcinoma: functional relevance and potential as biomarker. *Oncotarget.* 2015 Oct 25.

Koelsche C, Renner M, Johann P, Leiss I, Sahm F, Schimmack S, Wardelmann E, Renker EK, Schirmacher P, Korshunov A, von Deimling A,

Mechtersheimer G. Differential nuclear ATRX expression in sarcomas. *Histopathology.* 2015 Aug 20. doi: 10.1111/his.12812. [Epub ahead of

print] PubMed PMID: 26291601.

Kondylis V, Polykratis A, Ehlken H, Ochoa-Callejero L, Straub BK, Krishna-Subramanian S, Van TM, Curth HM, Heise N, Weih F, Klein U,

Schirmacher P, Kelliher M, Pasparakis M. NEMO Prevents Steatohepatitis and Hepatocellular Carcinoma by Inhibiting RIPK1 Kinase Activity-

Mediated Hepatocyte Apoptosis. *Cancer Cell.* 2015 Nov 9;28(5):582-98.

Liesenfeld DB, Grapov D, Fahrmann JF, Salou M, Scherer D, Toth R, Habermann N, Böhm J, Schrotz-King P, Gigic B, Schneider M, Ulrich A,

Herpel E, Schirmacher P, Fiehn O, Lampe JW, Ulrich CM. Metabolomics and transcriptomics identify pathway differences between visceral

and subcutaneous adipose tissue in colorectal cancer patients: the ColoCare study. *Am J Clin Nutr.* 2015 Aug;102(2):433-43.

Maass T, Marquardt J, Lee JS, Krupp M, Scholz-Kreisel P, Mogler C, Schirmacher P, Müller M, Westphal H, Galle PR, Teufel A. Increased

liver carcinogenesis and enrichment of stem cell properties in livers of Dickkopf 2 (Dkk2) deleted mice. *Oncotarget.* 2015 Mar 16. [Epub

ahead of print] PubMed PMID: 25826080.

Macher-Goeppinger S, Keith M, Tagscherer KE, Singer S, Winkler J, Hofmann TG, Pahernik S, Duensing S, Hohenfellner M, Kopitz J,

Schirmacher P, Roth W. PBRM1 (BAF180) protein is functionally regulated by p53-induced protein degradation in renal cell carcinomas. *J*

Pathol. 2015 Jul 16.

Mentzel T, Schirmacher P, Bierhoff E. [Neoplasms of the skin]. *Pathologe.* 2015 Feb;36(1):5-6. doi: 10.1007/s00292-014-2028-6. German.

PubMed PMID: 25630483.

Mogler C, Wieland M, König C, Hu J, Runge A, Korn C, Besemfelder E, Breitkopf-Heinlein K, Komljenovic D, Dooley S, Schirmacher P,

Longerich T, Augustin HG. Hepatic stellate cell-expressed endosialin balances fibrogenesis and hepatocyte proliferation during liver damage.

EMBO Mol Med. 2015 Feb 13;7(3):332-8.

Moskalev EA, Jandaghi P, Fallah M, Manoochehri M, Botla SK, Kolychev OV, Nikitin EA, Bubnov VV, von Knebel Doeberitz M, Strobel O,

Hackert T, Büchler MW, Giese N, Bauer A, Muley T, Warth A, Schirmacher P, Haller F, Hoheisel JD, Riazalhosseini Y. GHSR DNA

hypermethylation is a common epigenetic alteration of high diagnostic value in a broad spectrum of cancers. *Oncotarget*. 2015

Feb 28;6(6):4418-27.

Müller B, Bovet M, Yin Y, Stichel D, Malz M, González-Vallinas M, Middleton A, Ehemann V, Schmitt J, Muley T, Meister M, Herpel E, Singer

S, Warth A, Schirmacher P, Drasdo D, Matthäus F, Breuhahn K. Concomitant expression of far upstream element (FUSE) binding protein

(FBP) interacting repressor (FIR) and its splice variants induce migration and invasion of non-small cell lung cancer (NSCLC) cells. *J Pathol*.

2015 Nov;237(3):390-401. doi: 10.1002/path.4588. Epub 2015 Sep 8. PubMed PMID: 26177862.

Oliver Metzger M, Fuchs D, Tagscherer KE, Gröne HJ, Schirmacher P, Roth W. Inhibition of caspases primes colon cancer cells for 5-

fluorouracil-induced TNF- α -dependent necroptosis driven by RIP1 kinase and NF- κ B. *Oncogene*. 2015 Nov 2.

Pfarr N, Stenzinger A, Penzel R, Warth A, Dienemann H, Schirmacher P, Weichert W, Endris V. High-throughput diagnostic profiling of

clinically actionable gene fusions in lung cancer. *Genes Chromosomes Cancer*. 2015 Sep 23. Schmitt S, Kynast K, Schirmacher P, Herpel E.

[Maintenance of a research tissue bank : (Infra)structural and quality aspects]. *Pathologe*. 2015 Sep 21. [Epub ahead of print] German.

Pfeiffenberger J, Mogler C, Gotthardt DN, Schulze-Bergkamen H, Litwin T, Reuner U, Hefter H, Huster D, Schemmer P, Członkowska A,

Schirmacher P, Stremmel W, Cassiman D, Weiss KH. Hepatobiliary malignancies in Wilson disease. *Liver Int*. 2015 May;35(5):1615-22.

Protzer U, Böhm F, Longerich T, Seebach J, Heidary Navid M, Friemel J, Marques-Maggio E, Bawohl M, Heikenwalder M, Schirmacher P,

Dutkowski P, Clavien PA, Schemmer P, Schnitzler P, Gotthardt D, Müllhaupt B, Weber A. Molecular detection of hepatitis E virus (HEV) in

liver biopsies after liver transplantation. *Mod Pathol*. 2015 Apr;28(4):523-32. doi:10.1038/modpathol.2014.147. Epub 2014 Nov 21.

Schirmacher P. [Laudation for Prof. Dr. Dr. h.c. Manfred Dietel : Awarding of the Rudolf Virchow Medal 2015 of the German Society of

Pathology]. *Pathologe*. 2015 Nov 6. [Epub ahead of print] German.

Schmitt S, Kynast K, Schirmacher P, Herpel E. Challenges for qualitymanagement in implementation, maintenance, and sustainability of

research tissue biobanks. *Virchows Arch.* 2015 Aug 14.

Schuetz W, Schirmacher P, Eberhardt WE, Fischer JR, von der Schulenburg JM, Mezger J, Schumann C, Serke M, Zaun S, Dietel M, Thomas

M. EGFR mutation status and first-line treatment in patients with stage III/IV non-small cell lung cancer in Germany: an observational study.

Cancer Epidemiol Biomarkers Prev. 2015 Aug;24(8):1254-61.

Sievers E, Trautmann M, Kindler D, Huss S, Gruenewald I, Dirksen U, Renner M, Mechttersheimer G, Pedeutour F, Åman P, Nishio J,

Schildhaus HU, Kirfel J, Schirmacher P, Wardelmann E, Buettner R, Hartmann W. SRC inhibition represents a potential therapeutic strategy

in liposarcoma. *Int J Cancer.* 2015 Dec 1;137(11):2578-88.

Stenzinger A, Pfarr N, Penzel R, Wolf T, Schirmacher P, Endris V, Weichert W. Semiconductor-based sequencing of formalin-fixed, paraffin-embedded

colorectal cancer samples. *Oncologist.* 2015 May;20(5):e10-1.

von Laffert M, Stenzinger A, Hummel M, Weichert W, Lenze D, Warth A, Penzel R, Herbst H, Kellner U, Jurmeister P, Schirmacher P, Dietel

M, Klauschen F. ALK-FISH borderline cases in non-small cell lung cancer: Implications for diagnostics and clinical decision making. *Lung*

Cancer. 2015 Oct 23. pii: S0169-5002(15)30066-0.

von Laffert M, Warth A, Penzel R, Schirmacher P, Kerr KM, Elmerberger G, Schildhaus HU, Büttner R, Lopez-Rios F, Reu S, Kirchner T, Pauwels

P, Specht K, Drecoll E, Höfler H, Aust D, Baretton G, Bubendorf L, Stallmann S, Fisseler-Eckhoff A, Soltermann A, Tischler V, Moch H, Penault-

Llorca F, Hager H, Schäper F, Lenze D, Hummel M, Dietel M. Multicenter immunohistochemical ALK-testing of non-small-cell lung cancer

shows high concordance after harmonization of techniques and interpretation criteria. *J Thorac Oncol.* 2014 Nov;9(11):1685-92.

Wannhoff A, Rupp C, Friedrich K, Brune M, Knierim J, Flechtenmacher C, Sauer P, Stremmel W, Hov JR, Schirmacher P, Weiss KH, Gotthardt

DN. Inflammation But Not Biliary Obstruction Is Associated With Carbohydrate Antigen 19-9 Levels in Patients With Primary Sclerosing

Cholangitis. *Clin Gastroenterol Hepatol.* 2015 Jul 17. pii: S1542-3565(15)00972-6.

Warth A, Muley T, Kossakowski C, Stenzinger A, Schirmacher P, Dienemann H, Weichert W. Prognostic impact and clinicopathological

correlations of the cribriform pattern in pulmonary adenocarcinoma. *J Thorac Oncol.* 2015 Apr;10(4):638-44.

Warth A, Muley T, Kossakowski CA, Goeppert B, Schirmacher P, Dienemann H, Weichert W. Prognostic Impact of Intra-alveolar Tumor

Spread in Pulmonary Adenocarcinoma. *Am J Surg Pathol.* 2015 Jun;39(6):793-801.

Warth A, Stenzinger A, Andrusis M, Schlake W, Kempny G, Schirmacher P, Weichert W. Individualized medicine and demographic change as

determining workload factors in pathology: quo vadis? *Virchows Arch.* 2015 Oct 24. [Epub ahead of print] PubMed PMID: 26498186.

Weichert W, Kossakowski C, Harms A, Schirmacher P, Muley T, Dienemann H, Warth A. Proposal of a prognostically relevant grading

scheme for pulmonary squamous cell carcinoma. *Eur Respir J.* 2015 Nov 5. pii: ERJ-00937-2015.

Publications 2014

Ackermann S, Kocak H, Hero B, Ehemann V, Kahlert Y, Oberthuer A, Roels F, Theissen J, Odenthal M, Berthold F, Fischer M. (2014) FOXP1

inhibits cell growth and attenuates tumorigenicity of neuroblastoma. *BMC Cancer.* 14(840): 1-16. (IF:3.32)

Akhavanpoor M, Gleissner CA, Gorbatsch S, Doesch AO, Akhavanpoor H, Wangler S, Jahn F, Lasitschka F, Katus HA, Erbel C. (2014) CCL19

and CCL21 modulate the inflammatory milieu in atherosclerotic lesions. *Drug Des Devel Ther.* 8:2359-71. (IF: 3.03)

Alam MS, Gaida MM, Ogawa Y, Kolios AG, Lasitschka F, Ashwell JD. (2014) Counter-regulation of T cell effector function by differentially

activated p38. *J Exp Med.* 11(6):1257-70. (IF:13.91)

Andrusis M, Bauerle T, Goldschmidt H, Delorme S, Landgren O, Schirmacher P, Hillengass J. (2014) Infiltration patterns in monoclonal

plasma cell disorders: correlation of magnetic resonance imaging with matched bone marrow histology. *Eur J Radiol.* 83(6):970-4. (IF:2.16)

Andrusis M, Ellert E, Mandel U, Clausen H, Lehnert N, Raab MS, Goldschmidt H, Schwartz-Albiez R. (2014) Expression of Mucin-1 in multiple

myeloma and its precursors: correlation with glycosylation and subcellular localization. *Histopathology.* 64(6):799-806. (IF:3.30)

Anton A, Schott S, Kaip G, Rath M, Heil J, Aulmann S, Sinn HP. (2014) Ki-67 and p53 expression of the fallopian tube mucosa in breast

cancer patients with hereditary risk. *Arch Gynecol Obstet.* 289(5):1079-85. (IF:1.28)

Aulmann S, Sinn HP, Penzel R, Gilks CB, Schott S, Hassel JC, Schmidt D, Kommos F, Schirmacher P, Kommos S. (2014) Comparison of

molecular abnormalities in vulvar and vaginal melanomas. *Mod Pathol.* 27(10):1386-93. (IF:6.36)

Baccelli I, Stenzinger A*, Vogel V, Pfitzner BM, Klein C, Wallwiener M, Scharpf M, Saini M, Holland-Letz T, Sinn HP, Schneeweiss A, Denkert

C, Weichert W*, Trumpp A*. (2014) Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer

patients. *Oncotarget.* 5(18):8147-60. (IF: 6.63) *These authors contributed equally to the study

Bauer R, Dikow N, Brauer A, Kreuter M, Buss S, Evers C, Rocken C, Schnabel PA, Hinderhofer K, Ehlermann P, Katus HA, Kristen AV. (2014)

The "Wagshurst study": p.Val40Ile transthyretin gene variant causes late-onset cardiomyopathy. *Amyloid.* 21(4):267-75. (IF:2.51)

Bedossa P, Burt AD, Gouw AS, Lackner C, Schirmacher P, Terracciano L, Tiniakos D, Brain J, Bury Y, Cabibi D, Charlotte F, David E, Losi L,

Montani M, Pareja MJ, Wendum D, Wrba F, Ziol M, Ratzu V. (2014) Utility and appropriateness of the fatty liver inhibition of progression

(FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. *Hepatology*.

60(2):565-75. (IF:11.19)

Behr DS, Peitsch WK, Hametner C, Lasitschka F, Houben R, Schönhaar K, Michel J, Dollt C, Goebeler M, Marx A, Goerdts S, Schmieder A.

(2014) Prognostic value of immune cell infiltration, tertiary lymphoid structures and PD-L1 expression in Merkel cell carcinomas. *Int J Clin*

Exp Pathol. 7(11):7610-21. (IF: 1.78)

Beiser KU, Glaser A, Kleinschmidt K, Scholl I, Roth R, Li L, Gretz N, Mechtersheimer G, Karperien M, Marchini A, Richter W, Rappold GA.

(2014) Identification of novel SHOX target genes in the developing limb using a transgenic mouse model. *PLoS One*. 9(6):e98543. (IF:3.53)

Bergmann F, Aulmann S, Sipo B, Kloor M, von Heydebreck A, Schweipert J, Harjung A, Mayer P, Hartwig W, Moldenhauer G, Capper D,

Dyckhoff G, Freier K, Herpel E, Schleider A, Schirmacher P, Mechtersheimer G, Kloppel G, Blaker H. (2014) Acinar cell carcinomas of the

pancreas: a molecular analysis in a series of 57 cases. *Virchows Arch*. 465(6):661-72. (IF:2.56)

Bergmann F, Aulmann S, Welsch T, Herpel E, Werner J, Schirmacher P, Blaker H. (2014) Molecular analysis of pancreatic acinar cell

cystadenomas: Evidence of a non-neoplastic nature. *Oncol Lett*. 8(2):852-8. (IF:0.99)

Blank S, Rachakonda S, Keller G, Weichert W, Lordick F, Langer R, Springfield C, Bruckner T, Becker K, Kumar R, Ott K. (2014) A retrospective

comparative exploratory study on two methylentetrahydrofolate reductase (MTHFR) polymorphisms in esophagogastric cancer: the

A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients. *BMC Cancer*.

14:58. (IF:3.32)

Brinkhoff B, Ostroumov D, Heemcke J, Woller N, Gurlevik E, Manns MP, Longerich T, Zender L, Harty JT, Kubicka S, Kuhnel F, Wirth TC.

(2014) Microsphere priming facilitates induction of potent therapeutic T-cell immune responses against autochthonous liver cancers. *Eur J*

Immunol. 44(4):1213-24. (IF:4.52)

Brost S, Zimmermann A, Koschny R, Sykora J, Stremmel W, Schirmacher P, Walczak H, Ganten TM. (2014) Hepatocyte expression of TRAIL

pathway regulators correlates with histopathological and clinical parameters in chronic HCV infection. *Pathol Res Pract*. 210(2):83-91.

(IF:1.56)

Boecker W, Stenman G, Loening T, Andersson MK, Sinn HP, Barth P, Oberhellmann F, Bos I, Berg T, Marusic Z, SamoiloVA V, Buchwalow I.

(2014) Differentiation and histogenesis of syringomatous tumour of the nipple and low-grade adenosquamous carcinoma: evidence for a

common origin. *Histopathology*. 65(1):9-23. (IF:3.30)

Bubolz AM, Weissinger SE, Stenzinger A, Arndt A, Steinestel K, Bruderlein S, Cario H, Lubatschowski A, Welke C, Anagnostopoulos I, Barth TF,

Beer AJ, Moller P, Gottstein M, Viardot A, Lennerz JK. (2014) Potential clinical implications of BRAF mutations in histiocytic proliferations.

Oncotarget. 5(12):4060-70. (IF:6.63)

Budczies J, von Winterfeld M, Klauschen F, Kimritz AC, Daniel JM, Warth A, Endris V, Denkert C, Pfeiffer H, Weichert W, Dietel M,

Wittschieber D, Stenzinger A. (2014) Comprehensive analysis of clinico-pathological data reveals heterogeneous relations between

atherosclerosis and cancer. *J Clin Pathol*. 67(6):482-90. (IF:2.55)

Budczies J, von Winterfeld M, Klauschen F, Bockmayr M, Lennerz JK, Denkert C, Wolf T, Warth A, Dietel M, Anagnostopoulos I, Weichert W,

Wittschieber D, Stenzinger A. (2014) The landscape of metastatic progression patterns across major human cancers. *Oncotarget*. 6(1): 570-

583. (IF:6.63)

Bulut OC, Lindel K, Hauswald H, Brandt R, Klauschen F, Wolf J, Wolf T, Plinkert PK, Simon C, Weichert W, Stenzinger A. (2014) Clinical and

molecular characteristics of HNSCC patients with brain metastases: a retrospective study. *Eur Arch Otorhinolaryngol*. 271(6):1715-22.

(IF:1.60)

Campos B, Gal Z, Baader A, Schneider T, Sliwinski C, Gassel K, Bageritz J, Grabe N, von Deimling A, Beckhove P, Mogler C, Goidts V,

Unterberg A, Eckstein V, Herold-Mende C. (2014) Aberrant self-renewal and quiescence contribute to the aggressiveness of glioblastoma. *J*

Pathol. 234(1):23-33. (IF:7.33)

Casadonte R, Kriegsmann M, Zweynert F, Friedrich K, Baretton G, Otto M, Deininger SO, Paape R, Belau E, Suckau D, Aust D, Pilarsky C,

Kriegsmann J. (2014) Imaging mass spectrometry to discriminate breast from pancreatic cancer metastasis in formalin-fixed paraffinembedded

tissues. *Proteomics*. 14(7-8):956-64. (IF:3.97)

Castain C, Sempoux C, Brunt EM, Causse O, Heitzmann A, Hernandez-Prera JC, Le Bail B, Schirmacher P, Thung SN, Balabaud C, Bioulac-

Sage P. (2014) Coexistence of inflammatory hepatocellular adenomas with HNF1alpha-inactivated adenomas: is there an association?

Histopathology. 64(6):890-5. (IF:3.30)

Combs SE, Habermehl D, Kessel KA, Bergmann F, Werner J, Naumann P, Jager D, Buchler MW, Debus J. (2014) Prognostic impact of CA 19-9

on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer. *Ann Surg Oncol.* 21(8):2801-7. (IF:3.94)

Dapunt U, Giese T, Lasitschka F, Reinders J, Lehner B, Kretzer JP, Ewerbeck V, Hansch GM. (2014) On the inflammatory response in metalon-

metal implants. *J Transl Med.* 12:74. (IF:3.99)

Dapunt U, Giese T, Prior B, Gaida MM, Hansch GM. (2014) Infectious versus non-infectious loosening of implants: activation of T

lymphocytes differentiates between the two entities. *Int Orthop.* 38(6):1291-6. (IF:2.01)

Dapunt U, Maurer S, Giese T, Gaida MM, Hansch GM. (2014) The macrophage inflammatory proteins MIP1alpha (CCL3) and MIP2alpha

(CXCL2) in implant-associated osteomyelitis: linking inflammation to bone degradation. *Mediators Inflamm.* 2014:1-10. (IF:2.42)

D'Haese JG, Hartel M, Demir IE, Hinz U, Bergmann F, Buchler MW, Friess H, Ceyhan GO. (2014) Pain sensation in pancreatic diseases is not

uniform: the different facets of pancreatic pain. *World J Gastroenterol.* 20(27):9154-61. (IF:2.43)

Diederichs S. (2014) The four dimensions of noncoding RNA conservation. *Trends Genet.* 30(4):121-3. (IF:11.60)

Dihlmann S, Erhart P, Mehrabi A, Nickkholgh A, Lasitschka F, Bockler D, Hakimi M. (2014) Increased expression and activation of absent in

melanoma 2 inflammasome components in lymphocytic infiltrates of abdominal aortic aneurysms. *Mol Med.* 20(1):230-7. (IF:4.82)

Dihlmann S, Tao S, Echterdiek F, Herpel E, Jansen L, Chang-Claude J, Brenner H, Hoffmeister M, Kloor M. (2014) Lack of Absent in

Melanoma 2 (AIM2) expression in tumor cells is closely associated with poor survival in colorectal cancer patients. *Int J Cancer.*

135(10):2387-96. (IF:5.01)

Dreidax D, Bannert S, Henrich KO, Schroder C, Bender S, Oakes CC, Lindner S, Schulte JH, Duffy D, Schwarzl T, Saadati M, Ehemann V,

Benner A, Pfister S, Fischer M, Westermann F. (2014) p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is

hypermethylated and downregulated in MYCN-amplified neuroblastomas. *Hum Mol Genet.* 23(25):6826-37. (IF:6.68)

Dutrue C, Bergmann F, Rooman I, Zucknick M, Weichenhan D, Geiselhart L, Kaffenberger T, Rachakonda PS, Bauer A, Giese N, Hong C, Xie

H, Costello JF, Hoheisel J, Kumar R, Rehli M, Schirmacher P, Werner J, Plass C, Popanda O, Schmezer P. (2014) Early epigenetic

downregulation of WNK2 kinase during pancreatic ductal adenocarcinoma development. *Oncogene.* 33(26):3401-10. (IF:8.56)

Ehlken H, Krishna-Subramanian S, Ochoa-Callejero L, Kondylis V, Nadi NE, Straub BK, Schirmacher P, Walczak H, Kollias G, Pasparakis M.

(2014) Death receptor-independent FADD signalling triggers hepatitis and hepatocellular carcinoma in mice with liver parenchymal cellspecific

NEMO knockout. *Cell Death Differ.* 21(11):1721-32. (IF:8.39)

Elgohary N, Pellegrino R, Neumann O, Elzawahry HM, Saber MM, Zeeneldin AA, Geffers R, Ehemann V, Schemmer P, Schirmacher P,

ongerich T. (2014) Protumorigenic role of Timeless in hepatocellular carcinoma. *Int J Oncol.* 46(2):597-606. (IF:2.77)

Engeland CE, Grossardt C, Veinalde R, Bossow S, Lutz D, Kaufmann JK, Shevchenko I, Umansky V, Nettelbeck DM, Weichert W, Jager D, von

Kalle C, Ungerechts G. (2014) CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy. *Mol Ther.* 22(11):1949-

59. (IF:6.43)

Egenlauf B, Schnabel PA, Heußel CP, Warth A, Puderbach M, Herth FJF, Kreuter M. (2014) Seltene Ursache eines thorakalen Tumors.

Pneumologie. 11(3):255–258. (IF:0.00)

Erbel C, Akhavanpoor M, Okuyucu D, Wangler S, Dietz A, Zhao L, Stellos K, Little KM, Lasitschka F, Doesch A, Hakimi M, Dengler TJ, Giese T,

Blessing E, Katus HA, Gleissner CA. (2014) IL-17A influences essential functions of the monocyte/macrophage lineage and is involved in

advanced murine and human atherosclerosis. *J Immunol.* 193(9):4344-55. (IF:5.36)

Erhart P, Grond-Ginsbach C, Hakimi M, Lasitschka F, Dihlmann S, Bockler D, Hyhlik-Durr A. (2014) Finite element analysis of abdominal

aortic aneurysms: predicted rupture risk correlates with aortic wall histology in individual patients. *J Endovasc Ther.* 21(4):556-64. (IF:3.59)

Ertych N, Stolz A, Stenzinger A, Weichert W, Kaulfuss S, Burfeind P, Aigner A, Wordeman L, Bastians H. (2014) Increased microtubule

assembly rates influence chromosomal instability in colorectal cancer cells. *Nat Cell Biol.* 16(8):779-91. (IF:20.06)

Felix K, Schuck A, Gaida MM, Hinz U, Dovzhanskiy D, Werner J. (2014) Objective parameters aid the prediction of fistulas in pancreatic

surgery. *Exp Ther Med.* 8(3):719-26. (IF:0.94)

Fischer L*, Bergmann F*, Schimmack S, Hinz U, Priess S, Muller-Stich BP, Werner J, Hackert T, Buchler MW. (2014) Outcome of surgery for

pancreatic neuroendocrine neoplasms. *Br J Surg.* 101(11):1405-12. (IF:5.21) *These authors contributed equally to this work

Flehsig P, Kratochwil C, Schwartz LH, Rath D, Moltz J, Antoch G, Heussel CP, Rieser M, Warth A, Zabeck H, Kauczor HU, Haberkorn U,

Giesel FL. (2014) Quantitative volumetric CT-histogram analysis in N-staging of 18F-FDG-equivocal patients with lung cancer. *J Nucl Med.*

55(4):559-64. (IF:5.56)

Friedrich K, Wannhoff A, Kattner S, Brune M, Hov JR, Weiss KH, Antoni C, Dollinger M, Neumann-Haefelin C, Seufferlein T, Schemmer P,

Schirmacher P, Stremmel W, Gotthardt DN. (2014) PNPLA3 in end-stage liver disease: alcohol consumption, hepatocellular carcinoma development, and transplantation-free survival. *Gastroenterol Hepatol.* 29(7):1477-84. (IF:3.63)

Fritz S, Bergmann F, Grenacher L, Sgroi M, Hinz U, Hackert T, Buchler MW, Werner J. (2014) Diagnosis and treatment of autoimmune pancreatitis types 1 and 2. *Br J Surg.* 101(10):1257-65. (IF:5.21)

Fritz S, Klauss M, Bergmann F, Strobel O, Schneider L, Werner J, Hackert T, Buchler MW. (2014) Pancreatic Main-Duct Involvement in Branch-Duct IPMNs: An Underestimated Risk. *Ann Surg.* 260(5):848-56. (IF:7.19)

Gaber R, Watermann I, Kugler C, Reinmuth N, Huber RM, Schnabel PA, Vollmer E, Reck M, Goldmann T. (2014) Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC. *Diagn Pathol.* 9(1):165. (IF:2.41)

Georgi B, Korzeniewski N, Hadaschik B, Grulich C, Roth W, Sultmann H, Pahernik S, Hohenfellner M, Duensing S. (2014) Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (review). *Int J Oncol.* 45(4):1337-44. (IF:2.77)

Gewies A, Gorka O, Bergmann H, Pechloff K, Petermann F, Jeltsch KM, Rudelius M, Kriegsmann M, Weichert W, Horsch M, Beckers J, Wurst W, Heikenwalder M, Korn T, Heissmeyer V, Ruland J. (2014) Uncoupling malt1 threshold function from paracaspase activity results in destructive autoimmune inflammation. *Cell Rep.* 9(4):1292-305. (IF:7.21)

Goeppert B, Frauenschuh L, Renner M, Roessler S, Stenzinger A, Klauschen F, Warth A, Vogel MN, Mehrabi A, Hafezi M, Boehmer K, von Deimling A, Schirmacher P, Weichert W, Capper D. (2014) BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. *Mod Pathol.* 27(7):1028-34. (IF:6.36)

Goeppert B, Konermann C, Schmidt CR, Bogatyrova O, Geiselhart L, Ernst C, Gu L, Becker N, Zucknick M, Mehrabi A, Hafezi M, Klauschen F, Stenzinger A, Warth A, Breuhahn K, Renner M, Weichert W, Schirmacher P, Plass C, Weichenhan D. (2014) Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway. *Hepatology.* 59(2):544-54. (IF:11.19)

Gutschner T*, Hammerle M*, Pazaitis N*, Bley N, Fiskin E, Uckelmann H, Heim A, Grobeta M, Hofmann N, Geffers R, Skawran B, Longrich T, Breuhahn K, Schirmacher P, Muhleck B, Huttelmaier S*, Diederichs S*. (2014) Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is an important protumorigenic factor in hepatocellular carcinoma. *Hepatology.* 59(5):1900-11. (IF:11.19) *These authors contributed equally to this work

Halec G, Alemany L, Lloveras B, Schmitt M, Alejo M, Bosch FX, Tous S, Klaustermeier JE, Guimera N, Grabe N, Lahrmann B, Gissmann L,

Quint W, Bosch FX, de Sanjose S, Pawlita M, Retrospective International S, Group HPVTTTS, Retrospective International S, Group HPVTTTS.

(2014) Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. *J Pathol.*

234(4):441-51. (IF:7.33)

Harter PN, Zinke J, Scholz A, Tichy J, Zachskorn C, Kvasnicka HM, Goeppert B, Delloye-Bourgeois C, Hattingen E, Senft C, Steinbach JP, Plate

KH, Mehlen P, Schulte D, Mittelbronn M. (2014) Netrin-1 expression is an independent prognostic factor for poor patient survival in brain

metastases. *PLoS One.* 9(3):e92311. (IF:3.53)

Heger U, Blank S, Wiecha C, Langer R, Weichert W, Lordick F, Bruckner T, Dobritz M, Burian M, Springfield C, Grenacher L, Siewert JR,

Buchler M, Ott K. (2014) Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing

adenocarcinomas of the esophagogastric junction and stomach? *Ann Surg Oncol.* 21(5):1739-48. (IF:3.94)

Heigener DF, Deppermann KM, Pawel JV, Fischer JR, Kortsik C, Bohnet S, Eiff MV, Koester W, Thomas M, Schnabel PA, Reck M. (2014)

Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbine in elderly patients

(>70 years of age) with untreated non-small cell lung cancer. *Lung Cancer.* 84(1):62-6. (IF:3.74)

Heim D, Budczies J, Stenzinger A, Treue D, Hufnagl P, Denkert C, Dietel M, Klauschen F. (2014) Cancer beyond organ and tissue specificity:

next-generation-sequencing gene mutation data reveal complex genetic similarities across major cancers. *Int J Cancer.* 135(10):2362-9. (IF:

5.01)

Hoffmann K, Hinz U, Hillebrand N, Ganten T, Gotthardt D, Longerich T, Schirmacher P, Schemmer P. (2014) The MELD score predicts the

short-term and overall survival after liver transplantation in patients with primary sclerosing cholangitis or autoimmune liver diseases.

Langenbecks Arch Surg. 399(8):1001-9. (IF:2.16)

Hoffmann K, Muller-Butow V, Franz C, Hinz U, Longerich T, Buchler MW, Schemmer P. (2014) Factors predictive of survival after stapler

hepatectomy of hepatocellular carcinoma: a multivariate, single-center analysis. *Anticancer Res.* 34(2):767-76. (IF:1.87)

Hofmann H, von Haken R, Werner J, Kortjes N, Bergmann F, Schemmer P, Jager D, Radeleff B, Schulze-Bergkamen H. (2014) Unresectable

isolated hepatic metastases from solid pseudopapillary neoplasm of the pancreas: A case report of chemosaturation with high-dose

melphalan. *Pancreatology.* 14(6):546-9. (IF:2.50)

Hofner T, Macher-Goeppinger S, Klein C, Schillert A, Eisen C, Wagner S, Rigo-Watermeier T, Baccelli I, Vogel V, Trumpp A, Sprick MR. (2014)

Expression and prognostic significance of cancer stem cell markers CD24 and CD44 in urothelial bladder cancer xenografts and patients

undergoing radical cystectomy. *Urol Oncol.* 32(5):678-86. (IF: 3.36)

Holzmann C, Markowski DN, Koczan D, Helmke BM, Bullerdiek J. (2014) Genome-wide acquired uniparental disomy as well as chromosomal

gains and losses in an uterine epithelioid leiomyoma. *Mol Cytogenet.*7(1):19. (IF: 2.66)

Holzmann C, Markowski DN, Koczan D, K pker W, Helmke BM, Bullerdiek J. (2014) Cytogenetically normal uterine leiomyomas without

MED12-mutations - a source to identify unknown mechanisms of the development of uterine smooth muscle tumors. *Mol Cytogenet.*

7(1):88. (IF: 2.66)

Horwitz E, Stein I, Andreozzi M, Nemeth J, Shoham A, Pappo O, Schweitzer N, Tornillo L, Kanarek N, Quagliata L, Zreik F, Porat RM,

Finkelstein R, Reuter H, Koschny R, Ganten T, Mogler C, Shibolet O, Hess J, Breuhahn K, Grunewald M, Schirmacher P, Vogel A, Terracciano

L, Angel P, Ben-Neriah Y, Pikarsky E. (2014) Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to

sorafenib treatment. *Cancer Discov.* 4(6):730-43. (IF:15.93)

Hu J, Srivastava K, Wieland M, Runge A, Mogler C, Besemfelder E, Terhardt D, Vogel MJ, Cao L, Korn C, Bartels S, Thomas M, Augustin HG.

(2014) Endothelial cell-derived angiopoietin-2 controls liver regeneration as a spatiotemporal rheostat. *Science.* 343(6169):416-9.

(IF:31.48)

Huber J, Winkler A, Jakobi H, Bruckner T, Roth W, Hallscheidt P, Daneshvar K, Hohenfellner M, Pahernik S. (2014) Preoperative decision

making for renal cell carcinoma: cystic morphology in cross-sectional imaging might predict lower malignant potential. *Urol Oncol.* 32(1):37

e1-6. (IF:3.36)

Jortzik E, Farhadi M, Ahmadi R, T th K, Lohr J, Helmke BM, Kehr S, Unterberg A, Ott I, Gust R, Deborde V, Davioud-Charvet E, R au R,

Becker K, Herold-Mende C. (2014) Antiglioma activity of GoPI-sugar, a novel gold(I)-phosphole inhibitor: chemical synthesis, mechanistic

studies, and effectiveness in vivo. *Biochim Biophys Acta.* 1844(8):1415-26. (IF: 3.19)

Kahlert C, Fiala M, Musso G, Halama N, Keim S, Mazzone M, Lasitschka F, Pecqueux M, Klupp F, Schmidt T, Rahbari N, Scholch S, Pilarsky C,

Ulrich A, Schneider M, Weitz J, Koch M. (2014) Prognostic impact of a compartment-specific angiogenic marker profile in patients with

pancreatic cancer. *Oncotarget.* 5(24):12978-89. (IF:6.27)

Kahlert C, Pecqueux M, Halama N, Dienemann H, Muley T, Pfannschmidt J, Lasitschka F, Klupp F, Schmidt T, Rahbari N, Reissfelder C, Kunz

C, Benner A, Falk C, Weitz J, Koch M. (2014) Tumour-site-dependent expression profile of angiogenic factors in tumour-associated stroma

of primary colorectal cancer and metastases. *Br J Cancer*. 110(2):441-9. (IF:4.82)

Keleg S, Titov A, Heller A, Giese T, Tjaden C, Ahmad SS, Gaida MM, Bauer AS, Werner J, Giese NA. (2014) Chondroitin sulfate proteoglycan

CSPG4 as a novel hypoxia-sensitive marker in pancreatic tumors. *PLoS One*. 9(6):e100178. (IF:3.53)

Klemke M, Müller MH, Wosniok W, Markowski DN, Nimzyk R, Helmke BM, Bullerdiek J. (2014) Correlated expression of HMGA2 and PLAG1

in thyroid tumors, uterine leiomyomas and experimental models. *PLoS One*. 9(2):e88126. (IF: 3.53)

Koelsche C*, Renner M*, Hartmann W, Brandt R, Lehner B, Waldburger N, Alldinger I, Schmitt T, Egerer G, Penzel R, Wardelmann E,

Schirmacher P, von Deimling A, Mechtersheimer G. (2014) TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare

in other soft tissue sarcoma entities. *J Exp Clin Cancer Res*. 33:33. (IF:3.27) *These authors contributed equally to the study

Koelsche C, Sahm F, Paulus W, Mittelbronn M, Giangaspero F, Antonelli M, Meyer J, Lasitschka F, von Deimling A, Reuss D. (2014) BRAF

V600E expression and distribution in desmoplastic infantile astrocytoma/ganglioglioma. *Neuropathol Appl Neurobiol*. 40(3):337-44.

(IF:4.97)

Koelsche C, Schweizer L, Renner M, Warth A, Jones DT, Sahm F, Reuss DE, Capper D, Knosel T, Schulz B, Petersen I, Ulrich A, Renker EK,

Lehner B, Pfister SM, Schirmacher P, von Deimling A, Mechtersheimer G. (2014) Nuclear relocation of STAT6 reliably predicts NAB2-STAT6

fusion for the diagnosis of solitary fibrous tumour. *Histopathology*. 65(5):613-22. (IF:3.30)

Koenigkam-Santos M, Sommer G, Puderbach M, Safi S, Schnabel PA, Kauczor HU, Heussel CP. (2014) Primary intrathoracic malignant

mesenchymal tumours: computed tomography features of a rare group of chest neoplasms. *Insights Imaging*. 5(2):237-44. (IF)

Koenigkam Santos M, Muley T, Warth A, de Paula WD, Lederlin M, Schnabel PA, Schlemmer HP, Kauczor HU, Heussel CP, Puderbach M.

(2014) Morphological computed tomography features of surgically resectable pulmonary squamous cell carcinomas: impact on prognosis

and comparison with adenocarcinomas. *Eur J Radiol*. 83(7):1275-81. (IF:2.16)

Kommos S, Gilks CB, Penzel R, Herpel E, Mackenzie R, Huntsman D, Schirmacher P, Anglesio M, Schmidt D, Kommos F. (2014) A current

perspective on the pathological assessment of FOXL2 in adult-type granulosa cell tumours of the ovary. *Histopathology*. 64(3):380-8.

(IF:3.30)

Koschny R, Boehm C, Sprick MR, Haas TL, Holland H, Xu LX, Krupp W, Mueller WC, Bauer M, Koschny T, Keller M, Sinn P, Meixensberger J,

Walczak H, Ganten TM. (2014) Bortezomib sensitizes primary meningioma cells to TRAIL-induced apoptosis by enhancing formation of the

death-inducing signaling complex. *J Neuropathol Exp Neurol.* 73(11):1034-46. (IF:4.37)

Kossakowski CA, Morresi-Hauf A, Schnabel PA, Eberhardt R, Herth FJ, Warth A. (2014) Preparation of cell blocks for lung cancer diagnosis

and prediction: protocol and experience of a high-volume center. *Respiration.* 87(5):432-8. (IF:2.92)

Kreuter M, Ehlers-Tenenbaum S, Schaaf M, Oltmanns U, Palmowski K, Hoffmann H, Schnabel PA, Heußel CP, Puderbach M, Herth FJF,

Warth A. (2014) Treatment and outcome of lung cancer in idiopathic interstitial pneumonias. *SARCOIDOSIS VASC DIF.* 31(4):266-274.

(IF:1.74)Kriegsmann J, Arens N, Altmann C, Kriegsmann M, Casadonte R, Otto M. (2014) [Molecular pathological diagnostics of infections

in orthopedic pathology]. *Pathologe.* 35 Suppl 2:225-31. (IF:0.64)

Kriegsmann M, Casadonte R, Randau T, Gravius S, Pennekamp P, Strauss A, Oldenburg J, Wiczorek K, Deininger SO, Otto M, Kriegsmann J.

(2014) MALDI imaging of predictive ferritin, fibrinogen and proteases in haemophilic arthropathy. *Haemophilia.* 20(3):446-53. (IF:2.47)

Kriegsmann M, Endris V, Wolf T, Pfarr N, Stenzinger A, Loibl S, Denkert C, Schneeweiss A, Budczies J, Sinn P, Weichert W. (2014) Mutational

profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and

clinically relevant entity subgroup specific differences. *Oncotarget.* 5(20):9952-65. (IF:6.63)

Kristen AV, Biener M, Hegenbart U, Hardt S, Schnabel PA, Rocken C, Schonland SO, Katus HA, Giannitsis E. (2014) Evaluation of the clinical

use of midregional pro-atrial natriuretic peptide (MR-proANP) in comparison to N-terminal pro-B-type natriuretic peptide (NT-proBNP) for

risk stratification in patients with light-chain amyloidosis. *Int J Cardiol.* 176(3):1113-5. (IF:2.77)

Kristen AV, Rosenberg M, Lindenmaier D, Merkle C, Steen H, Andre F, Schonland SO, Schnabel PA, Schuster T, Rocken C, Giannitsis E, Katus

HA, Frey N. (2014) Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis. *Amyloid.* 21(3):202-10.

(IF:2.51)

Langer R, Becker K, Zlobec I, Gertler R, Sisic L, Büchler M, Lordick F, Slotta-Huspenina J, Weichert W, Höfler H, Feith M, Ott K. (2014).A

multifactorial histopathologic score for the prediction of prognosis of resected esophageal adenocarcinomas after neoadjuvant

chemotherapy. *Ann Surg Oncol.* 21(3):915-21. (IF:3.94)

Lebeau A, Kriegsmann M, Burandt E, Sinn HP. (2014) [Invasive breast cancer: the current WHO classification]. *Pathologe.* 35(1):7-17.

(IF:0.64)

Liebl F, Demir IE, Mayer K, Schuster T, D'Haese JG, Becker K, Langer R, Bergmann F, Wang K, Rosenberg R, Novotny AR, Feith M, Reim D,

Friess H, Ceyhan GO. (2014) The impact of neural invasion severity in gastrointestinal malignancies: a clinicopathological study. *Ann Surg.*

260(5):900-8. (IF:7.18)

Loibl S, von Minckwitz G, Schneeweiss A, Paepke S, Lehmann A, Rezai M, Zahm DM, Sinn P, Khandan F, Eidtmann H, Dohnal K, Heinrichs C,

Huober J, Pfitzner B, Fasching PA, Andre F, Lindner JL, Sotiriou C, Dykgers A, Guo S, Gade S, Nekljudova V, Loi S, Untch M, Denkert C. (2014)

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2

(her2) therapy in primary HER2-overexpressing breast cancer. *J Clin Oncol.* 32(29):3212-20. (IF:17.96)

Longerich T. (2014) [EEF1A2 inhibits the p53 function in hepatocellular carcinoma via PI3K/AKT/mTOR-dependent stabilization of

MDM4]. *Pathologe.* 35 Suppl 2:177-84. (IF:0.64)

Malz M, Bovet M, Samarin J, Rabenhorst U, Sticht C, Bissinger M, Roessler S, Bermejo JL, Renner M, Calvisi DF, Singer S, Ganzinger M,

Weber A, Gretz N, Zornig M, Schirmacher P, Breuhahn K. (2014) Overexpression of far upstream element (FUSE) binding protein (FBP)-

interacting repressor (FIR) supports growth of hepatocellular carcinoma. *Hepatology.* 60(4):1241-50. (IF:11.19)

Marek LA, Hinz TK, von Massenhausen A, Olszewski KA, Kleczko EK, Boehm D, Weiser-Evans MC, Nemenoff RA, Hoffmann H, Warth A,

Gozgit JM, Perner S, Heasley LE. (2014) Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma. *Mol Cancer Res.*

12(10):1460-9. (IF:4.50)

Marhenke S, Buitrago-Molina LE, Endig J, Orlik J, Schweitzer N, Klett S, Longerich T, Geffers R, Sanchez Munoz A, Dorrell C, Katz SF, Lechel A,

Weng H, Krech T, Lehmann U, Dooley S, Rudolph KL, Manns MP, Vogel A. (2014) p21 promotes sustained liver regeneration and

hepatocarcinogenesis in chronic cholestatic liver injury. *Gut.* 63(9):1501-12. (IF:13.32)

Markowski DN, Helmke BM, Bartnitzke S, Löning T, Bullerdiek J. (2014) Uterine fibroids: do we deal with more than one disease?. *Int J*

Gynecol Pathol. 33(6):568-72. (IF: 1.63)

Martins VC, Busch K, Juraeva D, Blum C, Ludwig C, Rasche V, Lasitschka F, Mastitsky SE, Brors B, Hielscher T, Fehling HJ, Rodewald HR.

(2014) Cell competition is a tumour suppressor mechanism in the thymus. *Nature* 509(7501):465-70. (IF:42.35)

Meister M, Belousov A, Xu EC, Schnabel P, Warth A, Hoffmann H, Dienemann H, Riedlinger J, Bodenmueller H, Zolg W, Herth FJF, Muley T.

(2014). Intra-tumor Heterogeneity of Gene Expression Profiles in Early Stage Non-Small Cell Lung Cancer. *Journal of Bioinformatics Research*

Studies 1(1):1-20. (IF:0.00)

Moskalev EA, Jandaghi P, Fallah M, Manoochehri M, Botla SK, Kolychev OV, Nikitin EA, Bubnov VV, von Knebel Doeberitz M, Strobel O,

Hackert T, Büchler MW, Giese N, Bauer A, Muley T, Warth A, Schirmacher P, Haller F, Hoheisel JD, Riazalhosseini Y. (2014) *GHSR* DNA

hypermethylation is a common epigenetic alteration of high diagnostic value in a broad spectrum of cancers *Oncotarget*. 6(6):4418-4427.

(IF: 6.63) Muley TR, Sianidou M, Thomas M, Bischoff H, Dienemann H, Meister M, Schneider MA, Schnabel PA, Warth A. (2014) Comparison

of two ERCC1 antibodies as prognostic and predictive biomarkers for early non-small cell lung cancer. *Anticancer Res*. 34(7):3707-13.

(IF:1.87)

Mueller S, Seitz HK, Schirmacher P, Straub BK. (2014) Nicht invasive versus invasive Beurteilung der Leberfibrose. *Gastro up2date*. 10:51-67.

(IF:0.00)

Muller-Stich BP, Senft JD, Lasitschka F, Shevchenko M, Billeter AT, Bruckner T, Kenngott HG, Fischer L, Gehrig T. (2014) Polypropylene,

polyester or polytetrafluoroethylene-is there an ideal material for mesh augmentation at the esophageal hiatus? Results from an

experimental study in a porcine model. *Hernia*. 18(6):873-81. (IF:2.09)

Nachmani D, Gutschner T, Reches A, Diederichs S*, Mandelboim O*. (2014) RNA-binding proteins regulate the expression of the immune

activating ligand MICB. *Nat Commun*. 5:4186. (IF:10.74). * These authors contributed equally to this work.

Nagel PD, Feld FM, Weissinger SE, Stenzinger A, Moller P, Lennerz JK. (2014) Absence of BRAF and KRAS hotspot mutations in primary

mediastinal B-cell lymphoma. *Leuk Lymphoma*. 55(10):2389-90. (IF:2.61)

Nagel PD, Stenzinger A, Feld FM, Herrmann MD, Bruderlein S, Barth TF, Marienfeld R, Endris V, Weichert W, Debatin KM, Westhoff MA,

Lessel D, Moller P, Lennerz JK. (2014) KIT mutations in primary mediastinal B-cell lymphoma. *Blood Cancer J*. 4(e241). (IF:2.88)

Oltmanns U, Kahn N, Palmowski K, Trager A, Wenz H, Heussel CP, Schnabel PA, Puderbach M, Wiebel M, Ehlers-Tenenbaum S, Warth A,

Herth FJ, Kreuter M. (2014) Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for

interstitial lung diseases. *Respiration*. 88(3):199-207. (IF:2.92)

Parpart S, Roessler S, Dong F, Rao V, Takai A, Ji J, Qin LX, Ye QH, Jia HL, Tang ZY, Wang XW. (2014). Modulation of miR-29 expression by β -

fetoprotein is linked to the hepatocellular carcinoma epigenome. *Hepatology*. 60(3):872-83. (IF:11.19)

Pathil A, Mueller J, Ludwig JM, Wang J, Warth A, Chamulitrat W, Stremmel W. (2014) Ursodeoxycholy lysophosphatidylethanolamide

attenuates hepatofibrogenesis by impairment of TGF-beta1/Smad2/3 signalling. *Br J Pharmacol*. 171(22):5113-26. (IF:4.99)

Pawella LM, Hashani M, Eiteneuer E, Renner M, Bartenschlager R, Schirmacher P, Straub BK. (2014) Perilipin discerns chronic from acute hepatocellular steatosis. *J Hepatol.* 60(3):633-42. (IF:10.40)

Pellegrino R, Calvisi DF, Neumann O, Kolluru V, Wesely J, Chen X, Wang C, Wuestefeld T, Ladu S, Elgohary N, Bermejo JL, Radlwimmer B, Zornig M, Zender L, Dombrowski F, Evert M, Schirmacher P, Longerich T. (2014) EEF1A2 inactivates p53 by way of PI3K/AKT/mTORdependent stabilization of MDM4 in hepatocellular carcinoma. *Hepatology.* 59(5):1886-99. (IF:11.19)

Petersen I, Fisseler-Eckhoff A, Warth A, Weichert W. (2014). Pathology as gatekeeper. New histopathological classification of NSCLC and molecular diagnostics. *Onkologie.* 20(10): 933-42. (IF:0.13)

Petersen I, Warth A. (2014) [Lung cancer. Developments, concepts and preview of the new WHO classification]. *Pathologie.* 35(6):547-56. (IF:0.64)

Quagliata L, Matter MS, Piscuoglio S, Arabi L, Ruiz C, Procino A, Kovac M, Moretti F, Makowska Z, Boldanova T, Andersen JB, Hammerle M, Tornillo L, Heim MH, Diederichs S, Cillo C*, Terracciano LM*. (2014) Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. *Hepatology.* 59(3):911-23. (IF:11.19)

Radtke JP, Kuru TH, Boxler S, Alt CD, Popenciu IV, Huettenbrink C, Klein T, Steinemann S, Bergstraesser C, Roethke M, Roth W, Schlemmer HP, Hohenfellner M, Hadaschik BA. (2014) Comparative Analysis of Transperineal Template Saturation Prostate Biopsy Versus Magnetic Resonance Imaging Targeted Biopsy with Magnetic Resonance Imaging-Ultrasound Fusion Guidance. *J Urol.* 193(1):87-94. (IF:3.75)

Radujkovic A, Hundemer M, Eisenbach C, Luft T, Penzel R, Goldschmidt H, Ho AD, Bellos F. (2014) Visceral leishmaniasis in a patient with relapsed multiple myeloma receiving high-dose melphalan and autologous stem cell transplant. *Leuk Lymphoma.* 16:1-3. (IF:2.61)

Reinmuth N, Kloos S, Warth A, Risch A, Muley T, Hoffmann H, Thomas M, Meister M. (2014) Insulin-like growth factor 1 pathway mutations and protein expression in resected non-small cell lung cancer. *Hum Pathol.* 45(6):1162-8. (IF:2.81)

Reinmuth N, Stumpf P, Stumpf A, Muley T, Kobinger S, Hoffmann H, Herth FJ, Schnabel PA, Bischoff H, Thomas M. (2014) Characteristics of lung cancer after a previous malignancy. *Respir Med.* 108(6):910-7. (IF:2.92)

Reissfelder C, Brand K, Sobiegalla J, Rahbari NN, Bork U, Schirmacher P, Buchler MW, Weitz J, Koch M. (2014) Chemotherapy-associated liver injury and its influence on outcome after resection of colorectal liver metastases. *Surgery.* 155(2):245-54. (IF:3.11)

Reuss DE, Habel A, Hagenlocher C, Mucha J, Ackermann U, Tessmer C, Meyer J, Capper D, Moldenhauer G, Mautner V, Frappart PO,

Schittenhelm J, Hartmann C, Hagel C, Katenkamp K, Petersen I, Mechtersheimer G, von Deimling A. (2014) Neurofibromin specific antibody

differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms. *Acta Neuropathol.* 127(4):565-72.

(*IF:9:78*)

Riener MO, Thiesler T, Hellerbrand C, Amann T, Cathomas G, Fritzsche FR, Dahl E, Bahra M, Weichert W, Terracciano L, Kristiansen G.

(2014) Loss of anterior gradient-2 expression is an independent prognostic factor in colorectal carcinomas. *Eur J Cancer.* 50(10):1722-30.

(*IF:4.82*)

Riplinger SM, Wabnitz GH, Kirchgessner H, Jahraus B, Lasitschka F, Schulte B, van der Pluijm G, van der Horst G, Hammerling GJ,

Nakchbandi I, Samstag Y. (2014) Metastasis of prostate cancer and melanoma cells in a preclinical in vivo mouse model is enhanced by Lplatin

expression and phosphorylation. *Mol Cancer.* 13:10. (*IF:5.40*)

Rocken C, Hofler H, Hummel M, Meyermann R, Zietz C, Schirmacher P. (2014) Participation in and support of clinical studies and other

scientific investigations - Statement of the German Society for Pathology. *Pathol Res Pract.* 210(11):705-12. (*IF:1.56*)

Roeder F, Lehner B, Schmitt T, Kasper B, Egerer G, Sedlaczek O, Grulich C, Mechtersheimer G, Wuchter P, Hensley FW, Huber PE, Debus J,

Bischof M. (2014) Excellent local control with IOERT and postoperative EBRT in high grade extremity sarcoma: results from a subgroup

analysis of a prospective trial. *BMC Cancer.* 14:350. (*IF:3.32*)

Roeder F, Ulrich A, Habl G, Uhl M, Saleh-Ebrahimi L, Huber PE, Schulz-Ertner D, Nikoghosyan AV, Alldinger I, Krempien R, Mechtersheimer

G, Hensley FW, Debus J, Bischof M. (2014) Clinical phase I/II trial to investigate preoperative dose-escalated intensity-modulated radiation

therapy (IMRT) and intraoperative radiation therapy (IORT) in patients with retroperitoneal soft tissue sarcoma: interim analysis. *BMC*

Cancer. 14(617). (*IF:3.32*)

Roessler S, Budhu A, Wang XW. (2014) Deciphering cancer heterogeneity: the biological space. *Front Cell Dev Biol.* 2:12. (*IF:0.00*)

Rudalska R, Dauch D, Longrich T, McJunkin K, Wuestefeld T, Kang TW, Hohmeyer A, Pesic M, Leibold J, von Thun A, Schirmacher P, Zuber J,

Weiss KH, Powers S, Malek NP, Eilers M, Sipos B, Lowe SW, Geffers R, Laufer S, Zender L. (2014) In vivo RNAi screening identifies a

mechanism of sorafenib resistance in liver cancer. *Nat Med.* 20(10):1138-46. (*IF: 28.05*)

Runge A, Hu J, Wieland M, Bergeest JP, Mogler C, Neumann A, Geraud C, Arnold B, Rohr K, Komljenovic D, Schirmacher P, Goerdts S,

Augustin HG. (2014) An inducible hepatocellular carcinoma model for preclinical evaluation of antiangiogenic therapy in adult mice. *Cancer*

Res. 74(15):4157-69. (IF:9.28)

Rupp C, Friedrich K, Folseraas T, Wannhoff A, Bode KA, Weiss KH, Schirmacher P, Sauer P, Stremmel W, Gotthardt DN. (2014) Fut2

genotype is a risk factor for dominant stenosis and biliary candida infections in primary sclerosing cholangitis. Aliment Pharmacol Ther.

39(8):873-82. (IF:5.48)

Rupp C, Herpel E, Schnitzler P, Zawierucha A, Zwickel P, Klute L, Kadmon M, Stremmel W, Gauss A. (2014) Protracted primary

cytomegalovirus infection presenting as ileoanal pouchitis in a non-immunosuppressed patient: a case report. J Med Case Rep. 8:163. (IF:)

Schmidt T, Sivic L, Blank S, Becker K, Weichert W, Bruckner T, Parakonhthun T, Langer R, Buchler MW, Siewert JR, Lordick F, Ott K. (2014)

Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas. Br J Cancer.

110(7):1712-20. (IF:4.82)

Schmolders J, Gravius S, Friedrich MJ, Kriegsmann M, Wirtz DC, Kriegsmann J. (2014) [Soft tissue tumor near the joint: hibernoma]. Z

Orthop Unfall. 152(4):366-8. (IF:0.62)

Schnabel PA, Junker K. (2014) [Neuroendocrine tumors of the lungs : From small cell lung carcinoma to diffuse idiopathic pulmonary

neuroendocrine cell hyperplasia]. Pathologe. 35(6):557-64. (IF: 0.64)

Schneeweiss A, Seitz J, Smetanay K, Schuetz F, Jaeger D, Bachinger A, Zorn M, Sinn HP, Marme F. (2014) Efficacy of Nab-Paclitaxel Does Not

Seem to Be Associated with SPARC Expression in Metastatic Breast Cancer. Anticancer Res. 34(11):6609-15. (IF:1.87)

Schneider M, Schuler J, Hofflin R, Korzeniewski N, Grulich C, Roth W, Teber D, Hadaschik B, Pahernik S, Hohenfellner M, Duensing S. (2014)

Phenotypic drug screening and target validation for improved personalized therapy reveal the complexity of phenotype-genotype

correlations in clear cell renal cell carcinoma. Urol Oncol. 32(6):877-84. (IF:3.36)

Schneider MR, Hiltwein F, Grill J, Blum H, Krebs S, Klanner A, Bauersachs S, Bruns C, Longerich T, Horst D, Brandl L, de Toni E, Herbst A,

Kolligs FT. (2014) Evidence for a role of E-cadherin in suppressing liver carcinogenesis in mice and men. Carcinogenesis. 35(8):1855-62.

(IF:5.27)

Schrock A, Bode M, Goke FJ, Bareiss PM, Schairer R, Wang H, Weichert W, Franzen A, Kirsten R, van Bremen T, Queisser A, Kristiansen G,

Heasley L, Bootz F, Lengerke C, Perner S. (2014) Expression and role of the embryonic protein SOX2 in head and neck squamous cell

carcinoma. Carcinogenesis. 35(7):1636-42. (IF:5.27)

Schroder-Braunstein J, Gras J, Brors B, Schwarz S, Szikszai T, Lasitschka F, Wabnitz G, Heidtmann A, Lee YS, Schiessling S, Leowardi C, Al-

Saeedi M, Ulrich A, Engelke A, Winter J, Samstag Y, Giese T, Meuer S. (2014) Initiation of an inflammatory response in resident intestinal

lamina propria cells -use of a human organ culture model. PLoS One. 9(5):e97780. (IF:3.53)

Schuhmann M, Bostanci K, Bugalho A, Warth A, Schnabel PA, Herth FJ, Eberhardt R. (2014) Endobronchial ultrasound-guided cryobiopsies

in peripheral pulmonary lesions: a feasibility study. Eur Respir J. 43(1):233-9. (IF:7.13)

Schwenger V, Hankel V, Seckinger J, Macher-Göppinger S, Morath C, Zeisbrich M, Zeier M, Kihm LP. (2014) Contrast-enhanced

ultrasonography in the early period after kidney transplantation predicts long-term allograft function. Transplant Proc. 46(10):3352-7. (IF:

0.98)

Seibold P, Vrieling A, Heinz J, Obi N, Sinn HP, Flesch-Janys D, Chang-Claude J. (2014) Pre-diagnostic smoking behaviour and poorer

prognosis in a German breast cancer patient cohort - Differential effects by tumour subtype, NAT2 status, BMI and alcohol intake. Cancer

Epidemiol. 38(4):419-26. (IF:2.56)

Senft J, Gehrig T, Lasitschka F, Linke GR, Shevchenko M, Bruckner T, Kenngott HG, Fischer L, Muller-Stich BP. (2014) Influence of weight

and structure on biological behavior of polypropylene mesh prostheses placed at the esophageal hiatus. J Laparoendosc Adv Surg Tech A.

24(6):383-90. (IF:1.19)

Simpfendorfer T, Kuru TH, Steinemann S, Bergstrasser C, Block S, Roth W, Roethke MC, Hohenfellner M, Hadaschik BA. (2014) Trocarsharpened

needles for image-guided prostate biopsy improve sample quality and performance: first clinical results. Endourol. 28(11):1384-

8. (IF:2.10)

Sinn BV, Striefler JK, Rudl MA, Lehmann A, Bahra M, Denkert C, Sinn M, Stieler J, Klauschen F, Budczies J, Weichert W, Stenzinger A,

Kamphues C, Dietel M, Riess H. (2014) KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal

adenocarcinoma. Pancreas. 43(4):578-83. (IF: 3.01)

Sinn HP, Flechtenmacher C, Aulmann S. (2014) [Diagnostics of benign ductal epithelial cell proliferation of the breast in biopsy material].

Pathologe. 35(1):18-25. (IF: 0.64)

Sinn HP, Helmchen B, Heil J, Aulmann S. (2014) [Lobular neoplasms and invasive lobular breast cancer]. Pathologe. 35(1):45-53. (IF:0.64)

Sonnet M, Claus R, Becker N, Zucknick M, Petersen J, Lipka DB, Oakes CC, Andrulis M, Lier A, Milsom MD, Witte T, Gu L, Kim-Wanner SZ,

Schirmacher P, Wulfert M, Gattermann N, Lubbert M, Rosenbauer F, Rehli M, Bullinger L, Weichenhan D, Plass C. (2014) Early aberrant

DNA methylation events in a mouse model of acute myeloid leukemia. *Genome Med.* 6(4):34. (IF:4.94)

Sprengel SD, Renker EK, Mechtersheimer G, Macher-Goppinger S, Weber MA. (2014) [A cystic lesion in the ulna. A simple one-look

diagnosis?]. *Radiologe.* 54(2):152-5. (IF:0.41)

Stampfl U, Bermejo JL, Sommer CM, Hoffmann K, Weiss KH, Schirmacher P, Schemmer P, Kauczor HU, Richter GM, Radeleff BA, Longerich

T. (2014) Efficacy and nontarget effects of transarterial chemoembolization in bridging of hepatocellular carcinoma patients to liver

transplantation: a histopathologic study. *J Vasc Interv Radiol.* 25(7):1018-26 e4. (IF:2.15)

Steinebrunner N, Mogler C, Vittas S, Hoyler B, Sandig C, Stremmel W, Eisenbach C. (2014) Pharmacologic cholinesterase inhibition

improves survival in acetaminophen-induced acute liver failure in the mouse. *BMC Gastroenterol.* 14:148. (IF:2.11)

Stenzinger A, Endris V, Pfarr N, Andrulis M, Johrens K, Klauschen F, Siebolts U, Wolf T, Koch PS, Schulz M, Hartschuh W, Goerdts S, Lennerz

JK, Wickenhauser C, Klapper W, Anagnostopoulos I, Weichert W. (2014) Targeted ultra-deep sequencing reveals recurrent and mutually

exclusive mutations of cancer genes in blastic plasmacytoid dendritic cell neoplasm. *Oncotarget.* 5(15):6404-13. (IF:6.63)

Stenzinger A, Kriegsmann M, Weichert W. (2014) [The role of pathology in the diagnostics of CUP syndrome]. *Radiologe.* 54(2):124-33.

(IF:0.41)

Stenzinger A, Pfarr N, Endris V, Penzel R, Jansen L, Wolf T, Herpel E, Warth A, Klauschen F, Kloor M, Roth W, Blaker H, Chang-Claude J,

Brenner H, Hoffmeister M, Weichert W. (2014) Mutations in POLE and survival of colorectal cancer patients - link to disease stage and

treatment. *Cancer Med.* 3(6):1527-38. (IF:2.94)

Stift J, Baba HA, Huber E, Federmann B, Fischer HP, Schmitt-Graeff A, Baurmann H, Bethge W, Schirmacher P, Wrba F, Greinix H, Fend F,

Schwerdtfeger R, Shulman HM, Wolff D, Longerich T, Liver Pathology Group of the German-Austrian-Swiss Working Group on Gv HD.

(2014) Consensus on the histopathological evaluation of liver biopsies from patients following allogeneic hematopoietic cell

transplantation. *Virchows Arch.* 464(2):175-90. (IF:2.56)

Stoecklin G, Diederichs S. (2014) tRNAs: new tricks from old dogs. *EMBO J.* 33(18):1981-3. (IF:10.75)

Strobel O, Hinz U, Gluth A, Hank T, Hackert T, Bergmann F, Werner J, Buchler MW. (2014) Pancreatic Adenocarcinoma: Number of Positive

Nodes Allows to Distinguish Several N Categories. *Ann Surg.* 260(5):848-55. (IF:7.19)

Sultmann H, Diederichs S. (2014) Long noncoding RNA: "LNCs" to cancer. *Eur Urol.* 65(6):1152-3. (IF:12.48)

Theile D, Gal Z, Warta R, Rigalli JP, Lahrmann B, Grabe N, Herold-Mende C, Dyckhoff G, Weiss J. (2014) Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma. *Cancer Biol Ther.* 15(4):436-42. (IF:3.63)

Thiele OC, Mertens C, Bacon C, Flechtenmacher C, Zaoui K, Mischkowski RA. (2014) Facial basal cell carcinoma with successive metastases to the neck, thyroid gland and lung. *J Craniomaxillofac Surg.* 42(5):489-91. (IF:2.60)

Thomann S, Longerich T, Bazhin AV, Mier W, Schemmer P, Ryschich E. (2014) Selective targeting of liver cancer with the endothelial marker CD146. *Oncotarget.* 5(18):8614-24. (IF:6.63)

Trautmann M, Sievers E, Aretz S, Kindler D, Michels S, Friedrichs N, Renner M, Kirfel J, Steiner S, Huss S, Koch A, Penzel R, Larsson O, Kawai A, Tanaka S, Sonobe H, Waha A, Schirmacher P, Mechtersheimer G, Wardelmann E, Buttner R, Hartmann W. (2014) SS18-SSX fusion protein-induced Wnt/beta-catenin signaling is a therapeutic target in synovial sarcoma. *Oncogene.* 33(42):5006-16. (IF:8.56)

Tschaharganeh DF, Xue W, Calvisi DF, Evert M, Michurina TV, Dow LE, Banito A, Katz SF, Kastenhuber ER, Weissmueller S, Huang CH, Lechel A, Andersen JB, Capper D, Zender L, Longerich T, Enikolopov G, Lowe SW. (2014) p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer. *Cell.* 158(3):579-92. (IF:33.12)

Urbanik T, Koehler BC, Wolpert L, Elssner C, Scherr AL, Longerich T, Kautz N, Welte S, Hovelmeyer N, Jager D, Waisman A, Schulze-Bergkamen H. (2014) CYLD deletion triggers nuclear factor-kappaB-signaling and increases cell death resistance in murine hepatocytes. *World J Gastroenterol.* 20(45):17049-64. (IF:2.43)

Vafaie M, Biener M, Mueller M, Schnabel PA, Andre F, Steen H, Zorn M, Schueler M, Blankenberg S, Katus HA, Giannitsis E. (2014) Analytically false or true positive elevations of high sensitivity cardiac troponin: a systematic approach. *Heart.* 100(6):508-14. (IF:6.02)

Veits L, Schupfner R, Hufnagel P, Penzel R, Freitag J, Strobel P, Kern MA, Schroder S, Neuhold N, Schmid KW, Schirmacher P, Hartmann A, Rieker RJ. (2014) KRAS, EGFR, PDGFR-alpha, KIT and COX-2 status in carcinoma showing thymus-like elements (CASTLE). *Diagn Pathol.* 9(116): 1-7. (IF:2.41)

von Laffert M, Warth A, Penzel R, Schirmacher P, Kerr KM, Elmerberger G, Schildhaus HU, Buttner R, Lopez-Rios F, Reu S, Kirchner T, Pauwels P, Specht K, Drecoll E, Hofler H, Aust D, Baretton G, Bubendorf L, Stallmann S, Fisseler-Eckhoff A, Soltermann A, Tischler V, Moch H, Penault-Llorca F, Hager H, Schaper F, Lenze D, Hummel M, Dietel M. (2014) Multicenter Immunohistochemical ALK-Testing of Non-Small-

Cell Lung Cancer Shows High Concordance after Harmonization of Techniques and Interpretation Criteria. *J Thorac Oncol.* 9(11):1685-92.

(*IF:5.80*)

von Laffert M, Penzel R, Schirmacher P, Warth A, Lenze D, Hummel M, Dietel M. (2014) Multicenter ALK testing in non-small-cell lung

cancer: results of a round robin test. *J Thorac Oncol.* 9(10):1464-9. (*IF:5.80*)

von Winterfeld M, Hoffmeister M, Ingold-Heppner B, Jansen L, Tao S, Herpel E, Schirmacher P, Dietel M, Chang-Claude J, Autschbach F,

Brenner H, Blaker H. (2014) Frequency of therapy-relevant staging shifts in colorectal cancer through the introduction of pN1c in the 7th

TNM edition. *Eur J Cancer.* 50(17):2958-65. (*IF:4.82*)

Waldburger N, Habbe N, Schulze F, Lindenmaier H, Ulrich F, Bechstein WO, Schirmacher P, Longerich T. (2014) Multifokale maligne

Transformation β -Catenin-aktivierter hepatozellulärer Adenome nach Missbrauch anaboler Steroide. *Gastro up2date.* 10:73-76. (*IF:0.00*)

Walstab J, Wohlfarth C, Hovius R, Schmitteckert S, Roth R, Lasitschka F, Wink M, Bonisch H, Niesler B. (2014) Natural compounds boldine

and menthol are antagonists of human 5-HT₃ receptors: implications for treating gastrointestinal disorders. *Neurogastroenterol Motil.*

26(6):810-20. (*IF:3.42*)

Wangerin H, Kristiansen G, Schlomm T, Stephan C, Gunia S, Zimpfer A, Weichert W, Sauter G, Erbersdobler A. (2014) CD57 expression in

incidental, clinically manifest, and metastatic carcinoma of the prostate. *Biomed Res Int.* 2014:356427. (*IF:00*)

Warta R, Herold-Mende C, Chaisaingmongkol J, Popanda O, Mock A, Mogler C, Osswald F, Herpel E, Kustner S, Eckstein V, Plass C, Plinkert

P, Schmezer P, Dyckhoff G. (2014) Reduced promoter methylation and increased expression of CSPG4 negatively influences survival of

HNSCC patients. *Int J Cancer.* 135(11):2727-34. (*IF:5.01*)

Warta R, Theile D, Mogler C, Herpel E, Grabe N, Lahrmann B, Plinkert PK, Herold-Mende C, Weiss J, Dyckhoff G. (2014) Association of drug

transporter expression with mortality and progression-free survival in stage IV head and neck squamous cell carcinoma. *PLoS One.*

9(9):e108908. (*IF:3.53*)

Warth A, Cortis J, Soltermann A, Meister M, Budczies J, Stenzinger A, Goepfert B, Thomas M, Herth FJ, Schirmacher P, Schnabel PA,

Hoffmann H, Dienemann H, Muley T, Weichert W. (2014) Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical

reappraisal of its prognostic role. *Br J Cancer.* 111(6):1222-9. (*IF:4.82*)

Warth A, Endris V, Penzel R, Weichert W. (2014) [Molecular pathology of lung cancer : State of the art 2014]. *Pathologe.* 35(6):565-73.

(*IF: 0.64*)

Warth A, Muley T, Dienemann H, Goeppert B, Stenzinger A, Schnabel PA, Schirmacher P, Penzel R, Weichert W. (2014) ROS1 expression

and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases. *Histopathology*. 65(2):187-94. (IF:3.30)

Warth A, Penzel R, Lindenmaier H, Brandt R, Stenzinger A, Herpel E, Goeppert B, Thomas M, Herth FJ, Dienemann H, Schnabel PA,

Schirmacher P, Hoffmann H, Muley T, Weichert W. (2014) EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient

outcome, interplay with morphology and immunophenotype. *Eur Respir J*. 43(3):872-83. (IF:7.13)

Warth A, Penzel R, Weichert W, Schirmacher P. (2014) Moderne Diagnostik des Lungenkarzinoms. *Onkologie* 3: 9-13. (IF:0.84)

Weichert W, Warth A. (2014) Early lung cancer with lepidic pattern: adenocarcinoma in situ, minimally invasive adenocarcinoma, and

lepidic predominant adenocarcinoma. *Curr Opin Pulm Med*. 20(4):309-16. (IF:2.96)

Weitnauer M, Schmidt L, Ng Kuet Leong N, Muenchau S, Lasitschka F, Eckstein V, Hubner S, Tuckermann J, Dalpke AH. (2014) Bronchial

epithelial cells induce alternatively activated dendritic cells dependent on glucocorticoid receptor signaling. *J Immunol*. 193(3):1475-84.

(IF:5.36)

Welte S, Urbanik T, Ellsner C, Kautz N, Koehler BC, Waldburger N, Bermejo JL, Pinna F, Weiss KH, Schemmer P, Jaeger D, Longerich T,

Breuhahn K, Schulze-Bergkamen H. (2014) Nuclear expression of the deubiquitinase CYLD is associated with improved survival in human

hepatocellular carcinoma. *PLoS One*. 9(10):e110591. (IF:3.53)

Winkler J, Ori A, Holzer K, Sticht C, Dauch D, Eiteneuer EM, Pinna F, Geffers R, Ehemann V, Andres-Pons A, Breuhahn K, Longerich T,

Bermejo JL, Gretz N, Zender L, Schirmacher P, Beck M, Singer S. (2014) Prosurvival function of the cellular apoptosis

susceptibility/importin-alpha1 transport cycle is repressed by p53 in liver cancer. *Hepatology*. 60(3):884-95. (IF:11.19)

Wolf J, Muller-Decker K, Flechtenmacher C, Zhang F, Shahmoradgoli M, Mills GB, Hoheisel JD, Boettcher M. (2014) An in vivo RNAi screen

identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation. *Oncogene*. 33(33):4273-8. (IF:8.56)

Zhou X, Tolstov Y, Arslan A, Roth W, Grüllich C, Pahernik S, Hohenfellner M, Duensing S. (2014) Harnessing the p53-PUMA Axis to Overcome

DNA Damage Resistance in Renal Cell Carcinoma. *Neoplasia*. 16(12):1028-35. (IF: 5.40)